Imdur (Isosorbide Mononitrate)

Isosorbide mononitrate is converted in the body to nitric oxide, which activates guanylate cyclase in vascular smooth muscle. This raises cyclic GMP levels, causing relaxation of arteries and veins, decreasing preload and afterload, and ultimately reducing myocardial oxygen demand.

The appropriate dose of Imdur is determined by the prescribing clinician based on the individual’s medical condition, response, and tolerability. Dosage may be adjusted over time, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for isosorbide mononitrate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Imdur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with short‑acting nitrates such as nitroglycerin, isosorbide mononitrate provides a longer duration of action and more stable plasma levels, allowing once‑daily dosing. Unlike beta‑blockers, it primarily reduces preload rather than heart‑rate, offering an alternative mechanism for patients who cannot tolerate beta‑blockade.

Imdur tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat, and direct sunlight to maintain stability throughout the shelf life.

Imdur is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the timing recommended by their prescriber, especially if the dose is being titrated.

The most serious risks include severe hypotension, syncope, and rare allergic reactions that may progress to anaphylaxis. Patients should seek immediate medical attention if they experience fainting, a sudden drop in blood pressure, or signs of a severe allergic response.

Imdur is contraindicated in patients with known hypersensitivity to isosorbide mononitrate or any other nitrate, those who have taken phosphodiesterase‑5 inhibitors within the past 24‑48 hours, and individuals with severe anemia or closed‑angle glaucoma. Clinicians must assess each patient’s medical history before prescribing.